Masahiro Nishibori Selected Research

Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)

12/2021	Anti-high mobility group box 1 monoclonal antibody suppressed hyper-permeability and cytokine production in human pulmonary endothelial cells infected with influenza A virus.
9/2020	Advanced glycation end products (AGEs) synergistically potentiated the proinflammatory action of lipopolysaccharide (LPS) and high mobility group box-1 (HMGB1) through their direct interactions.
1/2020	High Mobility Group Box 1 Expression in Oral Inflammation and Regeneration.
1/2018	Anti-HMGB1 Neutralizing Antibody Attenuates Periodontal Inflammation and Bone Resorption in a Murine Periodontitis Model.
10/2006	Stimulation of alpha7 nicotinic acetylcholine receptor inhibits CD14 and the toll-like receptor 4 expression in human monocytes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Masahiro Nishibori Research Topics

Disease

33	Inflammation (Inflammations) 11/2023 - 09/2002
21	Sepsis (Septicemia) 01/2024 - 02/2003
17	Neoplasms (Cancer) 01/2024 - 01/2005
12	Pain (Aches) 01/2024 - 01/2016
10	Neuralgia (Stump Neuralgia) 08/2022 - 01/2013
10	Brain Injuries (Brain Injury) 01/2022 - 09/2012
9	Infections 12/2021 - 08/2005
8	Neoplasm Metastasis (Metastasis) 12/2022 - 01/2016
8	Peripheral Nervous System Diseases (PNS Diseases) 03/2022 - 01/2016
8	Ischemia 10/2021 - 08/2006
8	Stroke (Strokes) 01/2021 - 06/2012
7	Reperfusion Injury 10/2021 - 08/2006
7	Hyperalgesia 06/2020 - 01/2016
7	Traumatic Brain Injuries (Traumatic Brain Injury) 05/2019 - 09/2012
6	Hypersensitivity (Allergy) 01/2022 - 06/2007
6	Brain Edema (Cerebral Edema) 02/2019 - 05/2011
5	Melanoma (Melanoma, Malignant) 09/2022 - 01/2016
5	Diabetes Complications 01/2021 - 03/2010
5	Pneumonia (Pneumonitis) 01/2019 - 06/2015
4	Epilepsy (Aura) 09/2023 - 08/2017
4	Neuroinflammatory Diseases 01/2022 - 01/2016
4	Infarction (Infarctions) 06/2012 - 12/2007
4	Brain Infarction 05/2011 - 12/2007
3	Human Influenza (Influenza) 12/2021 - 01/2018
3	Wounds and Injuries (Trauma) 07/2021 - 04/2019
3	Brain Ischemia (Cerebral Ischemia) 01/2021 - 05/2011
3	Encephalitis (Encephalitis, Rasmussen) 12/2020 - 08/2017
3	Thromboinflammation 09/2020 - 07/2016
3	Atherosclerosis 12/2018 - 02/2011
3	Edema (Dropsy) 10/2018 - 04/2016
3	Hepatitis 02/2008 - 09/2004
2	Trigeminal Nerve Diseases (Trigeminal Nerve Disorders) 01/2024 - 04/2021
2	Bites and Stings (Sting) 12/2023 - 12/2022
2	Endotoxemia 07/2023 - 10/2006
2	Cytokine Release Syndrome 07/2023 - 07/2016
2	Leukemia 12/2022 - 01/2018
2	Lung Neoplasms (Lung Cancer) 09/2022 - 01/2019
2	Hemolysis 01/2022 - 03/2018
2	Cognitive Dysfunction 01/2022 - 02/2019
2	Anaphylaxis (Anaphylactic Shock) 01/2022 - 02/2008
2	Shock 01/2022 - 12/2021
2	COVID-19 01/2022 - 01/2021
2	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 12/2021 - 10/2018
2	Spinal Cord Injuries (Spinal Cord Injury) 11/2021 - 01/2018

Drug/Important Bio-Agent (IBA)

71	HMGB1 Protein (HMG1)IBA 09/2023 - 12/2007
23	Monoclonal AntibodiesIBA 01/2024 - 12/2007
19	Proteins (Proteins, Gene)FDA Link 12/2023 - 02/2011
18	histidine-rich proteinsIBA 01/2024 - 11/2009
14	CytokinesIBA 08/2022 - 07/2005
13	LipopolysaccharidesIBA 07/2023 - 02/2003
10	Advanced Glycation End ProductsIBA 12/2023 - 03/2010
9	Biomarkers (Surrogate Marker)IBA 01/2023 - 01/2014
8	glycolaldehydeIBA 12/2023 - 09/2009
8	Histamine (Histamine Dihydrochloride)FDA Link 01/2022 - 09/2002
7	Toll-Like Receptor 4IBA 12/2023 - 10/2006
7	Neutralizing AntibodiesIBA 01/2021 - 02/2011
7	Interleukin-18 (Interleukin 18)IBA 08/2006 - 09/2002
6	Blood Proteins (Serum Proteins)IBA 01/2024 - 07/2016
6	Nuclear Proteins (Protein, Nuclear)IBA 01/2022 - 01/2016
6	LigandsIBA 12/2021 - 08/2006
6	Receptor for Advanced Glycation End ProductsIBA 12/2020 - 01/2016
5	Paclitaxel (Taxol)FDA LinkGeneric 01/2022 - 01/2016
5	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 12/2021 - 10/2006
5	Therapeutic UsesIBA 06/2020 - 01/2009
5	ThrombomodulinIBA 06/2020 - 01/2016
5	GlyceraldehydeIBA 01/2020 - 09/2009
4	Minocycline (Cyclops)FDA LinkGeneric 01/2022 - 12/2017
3	Phosphotransferases (Kinase)IBA 12/2023 - 10/2003
3	Adenosine Triphosphate (ATP)IBA 01/2022 - 01/2020
3	Clodronic Acid (Clodronate)IBA 01/2022 - 12/2017
3	EndotoxinsIBA 01/2021 - 09/2004
3	LipidsIBA 01/2021 - 08/2006
3	Glycoproteins (Glycoprotein)IBA 01/2021 - 12/2018
3	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 12/2020 - 01/2016
3	Interleukin-6 (Interleukin 6)IBA 01/2020 - 01/2016
3	InterleukinsIBA 01/2020 - 11/2005
3	CD146 AntigenIBA 01/2019 - 04/2018
3	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 04/2006 - 05/2003
2	InterferonsIBA 12/2023 - 12/2022
2	cyclic guanosine monophosphate-adenosine monophosphateIBA 12/2023 - 12/2022
2	Ribosomal Proteins (Ribosomal Protein)IBA 11/2023 - 04/2022
2	HMGB ProteinsIBA 09/2023 - 10/2021
2	Pentylenetetrazole (Metrazol)IBA 09/2023 - 08/2017
2	Kainic Acid (Kainate)IBA 09/2023 - 08/2017
2	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2023 - 01/2019
2	AntibodiesIBA 10/2022 - 06/2012
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 09/2022 - 11/2009
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 03/2022 - 10/2019
2	Glycyrrhizic Acid (Glycyrrhizin)IBA 01/2022 - 10/2014
2	Heme (Haem)IBA 01/2022 - 03/2018
2	ChromatinIBA 01/2022 - 10/2021
2	salicylhydroxamic acid (SHAM)IBA 10/2021 - 01/2016

Therapy/Procedure

20	Therapeutics 10/2022 - 05/2011
11	Ligation 08/2022 - 03/2010
6	Drug Therapy (Chemotherapy) 03/2022 - 01/2016
5	Intravenous Injections 07/2023 - 12/2007
4	Intraperitoneal Injections 08/2022 - 11/2011
3	Tooth Extraction (Tooth Extractions) 07/2021 - 01/2018
3	Transplantation 01/2018 - 04/2006
2	Injections 01/2022 - 12/2017